Curis (NASDAQ:CRIS) Price Target Lowered to $16.00 at HC Wainwright

Curis (NASDAQ:CRIS) had its price target decreased by HC Wainwright from $20.00 to $16.00 in a research note published on Monday,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com initiated coverage on Curis in a report on Saturday. They issued a “hold” rating for the company.

Curis Stock Performance

CRIS opened at $2.10 on Monday. The business’s 50-day simple moving average is $3.01 and its 200 day simple moving average is $3.86. The firm has a market capitalization of $17.78 million, a PE ratio of -0.27 and a beta of 3.49. Curis has a 52-week low of $2.10 and a 52-week high of $17.49.

Hedge Funds Weigh In On Curis

Hedge funds and other institutional investors have recently bought and sold shares of the business. CM Management LLC lifted its position in shares of Curis by 83.3% in the fourth quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock valued at $673,000 after buying an additional 100,000 shares during the last quarter. Focused Wealth Management Inc lifted its holdings in Curis by 9.5% during the 4th quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock valued at $181,000 after purchasing an additional 5,138 shares during the last quarter. Millennium Management LLC boosted its position in Curis by 92.6% during the fourth quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 12,287 shares during the period. Squarepoint Ops LLC bought a new position in Curis during the fourth quarter worth $35,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Curis in the fourth quarter valued at $607,000. Institutional investors own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.